No Data
No Data
Zejing Pharmaceutical-U (688266): Steady growth in performance, continued promotion of commercialization and innovation pipeline
Core view The company's revenue for the full year of 2023 was 386 million yuan, a year-on-year steady increase of 27.83%. Revenue for the first quarter of 2024 was 108 million yuan, maintaining year-on-year and month-on-month growth. Overall, the company's core products
Zejing Pharmaceutical-U (688266): Revenue continues to grow, and the differentiated pipeline has entered the harvest period
Maintain an “Overweight” rating. In view of changes in the hospital sales environment, the 2024/2025 revenue forecast was adjusted to 766/ 1,454 million yuan (originally 936/1,702 million yuan), and additional 2026 operations were added
Zejing Pharmaceutical (688266): Steady promotion of commercialized core products can be expected
Core view: The company released the 2023 annual report and the 2024 quarterly report: the company achieved revenue of 386 million yuan in 2023, an increase of 27.8% over the previous year; realized net profit to mother - 279 million yuan, a year-on-year decrease of 1.7 million yuan
Zejing Pharmaceutical (688266): The narrowing of losses is optimistic that the volume of new drugs will drive revenue growth
The company achieved revenue of 386 million yuan (+27.83%) in 2023, mainly due to sales volume of donafenib tablets; net loss to mother of 279 million yuan, loss decreased by 179 million yuan year on year; Q1-Q in 2023
Zejing Pharmaceutical (688266): Commercialization is progressing steadily, looking forward to the listing of Jacketinib
Event: The company released its 2023 annual report and achieved operating revenue of 390 million yuan (+27.8%) during the reporting period. The commercialization of donafenib is progressing steadily, and coverage continues to expand. The commercialization of donafenib progresses steadily, and it will be put into operation in 2023
SDIC Securities released a research report on April 22 stating that it maintains the purchase rating of Zejing Pharmaceuticals (688266.SH), and the target price is 64.20 yuan. The main reasons for the rating include: 1) A number of innovative drugs are gr
SDIC Securities released a research report on April 22 stating that it maintains the purchase rating of Zejing Pharmaceuticals (688266.SH), and the target price is 64.20 yuan. The main reasons for the rating include: 1) A number of innovative drugs are gradually entering the commercialization stage; 2) Early innovative drug pipelines have large reserves, and the potential for subsequent product pipelines is high. (Mainichi Keizai Shimbun)
No Data